Predict your next investment

Venture Capital
FINANCIAL | Investment Firms & Funds
peregrinevc.com

See what CB Insights has to offer

Investments

44

Portfolio Exits

8

Funds

4

About Peregrine Ventures

Peregrine Ventures a venture capital fund focusing on early-stage investments with a strong emphasis on Life Sciences and Information Technology

Peregrine Ventures Headquarter Location

6 Yoni Netanyahu Street

Or Yehuda, 60376,

Israel

+972-3-634 9990

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Peregrine Ventures Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Peregrine Ventures Rank

Latest Peregrine Ventures News

Peregrine Ventures : Portfolio Company Memic Announces $1B Valuation SPAC deal

Aug 19, 2021

08/13 08/19/2021 | 12:34pm EDT Message : *Required fields OR YEHUDA, Israel, Aug. 19, 2021 /PRNewswire/ --  Peregrine Ventures portfolio company Memic Innovative Surgery Ltd. has entered into a definitive agreement for a business combination with MedTech Acquisition Corporation (NASDAQ: MTAC), a publicly traded special purpose acquisition company (SPAC) focused on medical technology, including surgical robots. Memic is an Israeli based medical device company, founded and grown in Peregrine's incubator, that has developed the Hominis®, a robotic platform for surgical procedures. Following the completion of the business combination transaction – expected in the fourth quarter of 2021 – the combined company will operate under the Memic name with an estimated pro-forma equity value of more than $1 billion. Accordingly, Memic will apply to have its ordinary shares listed on the NASDAQ. "Memic brings to the market a robotic technology that enables robotic surgery with an accuracy not known before at an affordable price," said Eyal Lifschitz, co-founder and managing partner of Peregrine Ventures, who serves as the vice Chairman of Memic and also as chairman of the business committee on Memic's board of directors. Lifschitz, who was closely involved in the establishment of the company noted that "we made the connection with an unusually professional SPAC led by professionals in the medical robotic field." Lifschitz added: "The combination of Memic, led by CEO Dvir Cohen, and the MedTech Acquisition Company will enable Memic to realize its vision of global leadership for cutting edge robotic medicine." Memic's Hominis® platform is the first and only FDA-authorized surgical robot that features miniature humanoid-shaped arms, with shoulder, elbow, and wrist joints, providing human level dexterity and 360-degree articulation. Hominis' small, compact, and mobile design occupies a minimal footprint at a significant cost advantage compared to available robotic technology. The first FDA-authorized indication of Hominis® is in women's health, including benign hysterectomy via transvaginal approach, which is known to be less painful, has lower infection rates, has faster recovery and no visible scarring. Current robotic technology doesn't allow transvaginal access. Vaginal access is performed manually in 16% of all cases. Hominis® was developed to address the anatomical barriers and accessibility challenges that have up to now limited the use of robotic technology in this kind of surgery. Memic received its initial investment from Peregrine in Peregrine Ventures' incubator and received extensive financial support and guidance from Peregrine since the company's inception. Over the years, Peregrine has played a key role in forming Memic's Business Development and IP strategy and in assisting the company through the product development and the clinical stage processes. Peregrine, as the major stake holder in Memic, has led all Memic's financing rounds and directly contributed to the rapid growth in the company's valuation over the past years. Memic has applied for approval of its Hominis® system in countries outside the U.S. including the CE Mark from the European Union. As part of its R&D efforts, Memic plans to pursue general surgery and transluminal indications for the system. About Peregrine Ventures Peregrine Ventures was founded in 2001 by serial entrepreneurs Eyal Lifschitz and Boaz Lifschitz, who have been active in the establishment of startups since the 1990s. Over the years, they have been joined by partners Lior Shahory, Tamir Tal, David Eldar and Tal Carasso. Among the fields of investment by Peregrine today: pharma-oncology, medical devices, implants, disposable equipment, and digital health. To date, Peregrine has had 13 exits, not including Memic, with an accumulated value of more than $2 billion, including Valtech and Neovasc. Peregrine's portfolio includes fast growing companies, each of them with a valuation of hundreds of millions of dollars. About Memic Memic was founded in 2013 and based in Tel Aviv, Israel with a wholly owned subsidiary based in Fort Lauderdale, Florida, is a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology. For more information, visit: https://memicmed.com . Media contact:

Peregrine Ventures Investments

44 Investments

Peregrine Ventures has made 44 investments. Their latest investment was in Variantyx as part of their Series C - II on November 11, 2021.

CBI Logo

Peregrine Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/15/2021

Series C - II

Variantyx

$6M

Yes

3

9/23/2021

Series B

Blue White Robotics

$37M

No

2

8/16/2021

Series B

BrainQ

$40M

Yes

3

7/14/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

7/7/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/15/2021

9/23/2021

8/16/2021

7/14/2021

7/7/2021

Round

Series C - II

Series B

Series B

Series C

Series B

Company

Variantyx

Blue White Robotics

BrainQ

Subscribe to see more

Subscribe to see more

Amount

$6M

$37M

$40M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

2

3

10

10

Peregrine Ventures Portfolio Exits

8 Portfolio Exits

Peregrine Ventures has 8 portfolio exits. Their latest portfolio exit was CartiHeal on August 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/30/2021

Acquired

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/30/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Peregrine Ventures Fund History

4 Fund Histories

Peregrine Ventures has 4 funds, including GrowthPeregrine.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/10/2020

GrowthPeregrine

$101M

1

12/9/2019

Peregrine 4

Subscribe to see more

$99M

10

9/1/2007

Peregrine II

Subscribe to see more

$99M

10

12/31/2001

Peregrine I

Subscribe to see more

$99M

10

Closing Date

11/10/2020

12/9/2019

9/1/2007

12/31/2001

Fund

GrowthPeregrine

Peregrine 4

Peregrine II

Peregrine I

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$101M

$99M

$99M

$99M

Sources

1

10

10

10

Peregrine Ventures Team

3 Team Members

Peregrine Ventures has 3 team members, including current Founder, Managing Partner, Eyal Lifschitz.

Name

Work History

Title

Status

Eyal Lifschitz

Founder, Managing Partner

Current

Boaz Lifschitz

General Partner

Current

Gil Weil

General Partner

Former

Name

Eyal Lifschitz

Boaz Lifschitz

Gil Weil

Work History

Title

Founder, Managing Partner

General Partner

General Partner

Status

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.